Uncategorized
Allergan acquires RetroSense Therapeutics
Allergan acquired all assets of RetroSense Therapeutics and global rights to RST-001, a novel gene therapy for retinitis pigmentosa, the companies announced in a press release.Allergan paid RetroSense an initial cash payment of $60 million and agreed to make potential regulatory and commercialization milestone payments related to RST-001.